Parallel Advisors LLC Increases Stock Position in Elanco Animal Health Incorporated $ELAN

Parallel Advisors LLC grew its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 66.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,432 shares of the company’s stock after purchasing an additional 2,572 shares during the quarter. Parallel Advisors LLC’s holdings in Elanco Animal Health were worth $92,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Yousif Capital Management LLC acquired a new stake in Elanco Animal Health during the first quarter worth approximately $119,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Elanco Animal Health during the first quarter worth approximately $111,000. Comerica Bank raised its holdings in Elanco Animal Health by 46.4% during the first quarter. Comerica Bank now owns 49,680 shares of the company’s stock worth $522,000 after purchasing an additional 15,754 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Elanco Animal Health during the first quarter worth approximately $891,000. Finally, GAMMA Investing LLC raised its holdings in Elanco Animal Health by 1,743.8% during the first quarter. GAMMA Investing LLC now owns 12,390 shares of the company’s stock worth $130,000 after purchasing an additional 11,718 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a report on Thursday, July 17th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Finally, Piper Sandler lifted their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.33.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $18.76 on Thursday. The firm’s fifty day moving average price is $17.01 and its 200 day moving average price is $13.61. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $19.35. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The firm has a market cap of $9.32 billion, a price-to-earnings ratio of 21.82, a price-to-earnings-growth ratio of 3.44 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.